396 related articles for article (PubMed ID: 26563258)
1. Antimitotic drugs in the treatment of cancer.
van Vuuren RJ; Visagie MH; Theron AE; Joubert AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1101-12. PubMed ID: 26563258
[TBL] [Abstract][Full Text] [Related]
2. Photopharmacology of Antimitotic Agents.
Kirchner S; Pianowski Z
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628467
[TBL] [Abstract][Full Text] [Related]
3. Taxanes, microtubules and chemoresistant breast cancer.
McGrogan BT; Gilmartin B; Carney DN; McCann A
Biochim Biophys Acta; 2008 Apr; 1785(2):96-132. PubMed ID: 18068131
[TBL] [Abstract][Full Text] [Related]
4. Elaboration of thorough simplified vinca alkaloids as antimitotic agents based on pharmacophore similarity.
Zheng J; Deng L; Chen M; Xiao X; Xiao S; Guo C; Xiao G; Bai L; Ye W; Zhang D; Chen H
Eur J Med Chem; 2013 Jul; 65():158-67. PubMed ID: 23708010
[TBL] [Abstract][Full Text] [Related]
5. Microtubule destabilising agents: far more than just antimitotic anticancer drugs.
Bates D; Eastman A
Br J Clin Pharmacol; 2017 Feb; 83(2):255-268. PubMed ID: 27620987
[TBL] [Abstract][Full Text] [Related]
6. Tubulin Proteins in Cancer Resistance: A Review.
Kamal MA; Al-Zahrani MH; Khan SH; Khan MH; Al-Subhi HA; Kuerban A; Aslam M; Al-Abbasi FA; Anwar F
Curr Drug Metab; 2020; 21(3):178-185. PubMed ID: 32101117
[TBL] [Abstract][Full Text] [Related]
7. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.
Shi J; Orth JD; Mitchison T
Cancer Res; 2008 May; 68(9):3269-76. PubMed ID: 18451153
[TBL] [Abstract][Full Text] [Related]
8. The proliferation rate paradox in antimitotic chemotherapy.
Mitchison TJ
Mol Biol Cell; 2012 Jan; 23(1):1-6. PubMed ID: 22210845
[TBL] [Abstract][Full Text] [Related]
9. Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead.
Martino E; Casamassima G; Castiglione S; Cellupica E; Pantalone S; Papagni F; Rui M; Siciliano AM; Collina S
Bioorg Med Chem Lett; 2018 Sep; 28(17):2816-2826. PubMed ID: 30122223
[TBL] [Abstract][Full Text] [Related]
10. Recent advances of kinesin motor inhibitors and their clinical progress.
Voultsiadou A; Sarli V
Rev Recent Clin Trials; 2011 Sep; 6(3):271-7. PubMed ID: 21682672
[TBL] [Abstract][Full Text] [Related]
11. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
Perez EA
Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
[TBL] [Abstract][Full Text] [Related]
12. Tubulin interacting agents: novel taxanes and epothilones.
Agrawal NR; Ganapathi R; Mekhail T
Curr Oncol Rep; 2003 Mar; 5(2):89-98. PubMed ID: 12583825
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
14. Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest.
Kim JH; Yoo HI; Kang HS; Ro J; Yoon S
Biochem Biophys Res Commun; 2012 Feb; 418(1):98-103. PubMed ID: 22244892
[TBL] [Abstract][Full Text] [Related]
15. Chromosome alignment-maintaining phosphoprotein CHAMP1 plays a role in cell survival through regulating Mcl-1 expression.
Hino M; Iemura K; Ikeda M; Itoh G; Tanaka K
Cancer Sci; 2021 Sep; 112(9):3711-3721. PubMed ID: 34107118
[TBL] [Abstract][Full Text] [Related]
16. CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway.
Hung CM; Lin YC; Liu LC; Kuo SC; Ho CT; Way TD
Chem Biol Interact; 2016 Dec; 260():1-12. PubMed ID: 27769712
[TBL] [Abstract][Full Text] [Related]
17. 20th-century advances in drug therapy in oncology--Part. II.
Dutcher JP; Novik Y; O'Boyle K; Marcoullis G; Secco C; Wiernik PH
J Clin Pharmacol; 2000 Oct; 40(10):1079-92. PubMed ID: 11028247
[TBL] [Abstract][Full Text] [Related]
18. Development of new cancer therapeutic agents targeting mitosis.
Miglarese MR; Carlson RO
Expert Opin Investig Drugs; 2006 Nov; 15(11):1411-25. PubMed ID: 17040200
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
Fojo T; Menefee M
Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
[TBL] [Abstract][Full Text] [Related]
20. In Search of Panacea-Review of Recent Studies Concerning Nature-Derived Anticancer Agents.
Przystupski D; Niemczura MJ; Górska A; Supplitt S; Kotowski K; Wawryka P; Rozborska P; Woźniak K; Michel O; Kiełbik A; Bartosik W; Saczko J; Kulbacka J
Nutrients; 2019 Jun; 11(6):. PubMed ID: 31242602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
